Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
27.11.2009 Major European regulatory milestone in cardiovascular protection for Micardis® (telmisartan): Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients - For medical media, outside the US only
27.11.2009 Boehringer Ingelheim and Vectura conclude collaboration
18.11.2009 Boehringer Ingelheim and GlaxoSmithKline back EFA`s call for urgent improvements in care for people with lung disease this World COPD Day
16.11.2009 Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder (HSDD) - For medical media, outside the US only
02.11.2009 Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX technology platform
29.10.2009 Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products
26.10.2009 Boehringer Ingelheim Animal Health closes deal to acquire a significant portion of the Fort Dodge Animal Health Business from Pfizer - For medical media, outside the US only
23.10.2009 CHMP issues positive opinion for Micardis® (telmisartan) as the first treatment in its class to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients - For medical media, outside the US only
19.10.2009 FDA approves Micardis® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors - For medical media, outside the US only
19.10.2009 FDA approves Twynsta® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours - For medical media, outside the US only
14.10.2009 Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease - For medical media, outside the US only
07.10.2009 Access to HIV medication
28.09.2009 Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin - For medical media, outside the US only
22.09.2009 Boehringer Ingelheim Animal Health enters into agreement to acquire certain assets of Fort Dodge Animal Health from Pfizer - For medical media, outside the US only
15.09.2009 Early administration of Aggrenox® is effective and safe after acute ischaemic stroke or TIA - For medical media, outside the US only
15.09.2009 New analysis supports tiotropium as initial maintenance therapy for COPD - For medical media, outside the US only
14.09.2009 ERS COPD Research Award 2009 sponsored by Boehringer Ingelheim
11.09.2009 New data show patients with chronic low back pain maintained pain reduction on duloxetine
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed